INFLIXIMAB, DS-8201a, IMFINZI 50 mg/mL concentrate for solution for infusion., MYCOPHENOLATE MOFETIL, PERTUZUMAB
DESTINY-Breast07
Phase 2 small_molecule active
Quick answer
INFLIXIMAB, DS-8201a, IMFINZI 50 mg/mL concentrate for solution for infusion., MYCOPHENOLATE MOFETIL, PERTUZUMAB for HER2-positive Metastatic Breast Cancer is a Phase 2 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- HER2-positive Metastatic Breast Cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active